Related Experiment Video
Updated: May 12, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
RhoGEF12 controls cardiac remodeling by integrating G protein- and integrin-dependent signaling cascades
Mikito Takefuji1, Marcus Krüger, Kishor K Sivaraj
1Department of Pharmacology, Max Planck Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany.
Insights
Rho guanine nucleotide exchange factor 12 (RhoGEF12) is crucial in heart failure development. Inhibiting RhoGEF12 in mice protected against cardiac remodeling and improved survival, suggesting it as a therapeutic target.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Heart Failure Pathogenesis
Background:
- Cardiac remodeling, including hypertrophy and fibrosis, is central to heart failure.
- The small GTPase RhoA is implicated in cardiomyocyte growth, but its activation mechanisms and in vivo relevance are unclear.
Purpose of the Study:
- To identify Rho guanine nucleotide exchange factors (RhoGEFs) activated during cardiac pressure overload.
- To elucidate the role of RhoGEF12 in cardiac remodeling and heart failure.
Main Methods:
- Mass spectrometry to identify activated RhoGEFs in vivo.
- In vitro studies on stretch-induced RhoA activation and gene transcription.
- In vivo studies using cardiomyocyte-specific RhoGEF12 deletion in mice.
Main Results:
- RhoGEF12 was identified as a key player in cardiac remodeling.
- RhoGEF12 mediates stretch-induced RhoA activation and hypertrophic gene transcription, dependent on integrin β1 and G12/13 proteins.
- Cardiomyocyte-specific deletion of RhoGEF12 protected mice from pressure overload-induced heart failure.
- RhoGEF12 deficiency improved survival in mice with pre-existing hypertrophy.
Conclusions:
- RhoGEF12 integrates stretch-induced signaling in cardiomyocytes.
- RhoGEF12 is a potential therapeutic target for pressure overload-induced heart failure.
Abstract:
Structural cardiac remodeling, including hypertrophy and fibrosis, plays a crucial role in the pathogenesis of heart failure. In vitro studies suggested a role of the small GTPase RhoA in hypertrophic cardiomyocyte growth, but neither the molecular mechanisms leading to RhoA activation nor their relevance in vivo are known. We use here a mass spectrometric approach to identify Rho guanine nucleotide exchange factors (RhoGEFs) activated during cardiac pressure overload in vivo and show that RhoGEF12 is a central player during cardiac remodeling. We show that RhoGEF12 is required for stretch-induced RhoA activation and hypertrophic gene transcription in vitro and that its activation depends on integrin β1 and heterotrimeric G proteins of the G12/13 family. In vivo, cardiomyocyte-specific deletion of RhoGEF12 protects mice from overload-induced hypertrophy, fibrosis, and development of heart failure. Importantly, in mice with preexisting hypertrophy, induction of RhoGEF12 deficiency protects from cardiac decompensation, resulting in significantly increased long-term survival. Collectively, RhoGEF12 acts as an integrator of stretch-induced signaling cascades in cardiomyocytes and is an interesting new target for therapeutic intervention in patients with pressure overload-induced heart failure.
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
TGF - β Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Activation and Inactivation of G Proteins
Regulation of Angiogenesis and Blood Supply

